Stephanie Duncanson

Stephanie Duncanson is Ovie Therapeutics CBO leading business development and intellectual property. Stephanie is  also the founder and CEO of BioProspero partners, a consulting company providing unparalleled scientific and operational support to empower emerging biotechs.

Stephanie is an experienced independent consultant specializing in strategic and operational planning for small biotech companies. With a background in corporate strategy and business development, Stephanie has played a crucial role in company growth from small series A entities to publicly-traded, clinical-stage companies. Her expertise includes driving corporate strategy, aligning cross-functional objectives, leading business development efforts, and managing operational functions during periods of rapid growth. Stephanie's diverse consulting experience includes working with clients of all sizes in the life sciences industry, from start-ups to large biopharma companies.

She holds a PhD in bioengineering from Georgia Tech, where her research focused on cell-based therapies, immunology, and biomaterials, and a B.S. in Chemical Engineering from Northeastern University.